Catalyst Event
Novartis AG (NVS) · Earnings Release
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/28/2026, 12:00:00 AM
Reported Q1 2026 earnings on 2026-04-28 with net sales of $13.1B (-1% USD) and core EPS of $1.99 (-13% USD), missing analyst expectations. The results were impacted by US generic erosion, though priority brands showed strong growth. Full-year guidance was reaffirmed.
Korean Translation
2026년 4월 28일, 2026년 1분기 실적 발표. 순매출 131억 달러(-1%) 및 핵심 EPS 1.99달러(-13%)로 시장 예상치를 하회함. 미국 내 제네릭 경쟁 심화가 실적에 영향을 미쳤으나 주요 브랜드는 견조한 성장을 보이며 연간 가이던스를 유지함.
Related Recent Events
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-27. Medium importance estimated as earnings releases for high-growth companies typically result in ≥5% price movement. Analysts forecast EPS of approximately $2.93 forecasted.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
High importance estimated as earnings releases for major pharma often result in >10% price movement. Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.87 and revenue of $11.35 billion forecasted.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly reported Q1 2026 revenue of $19.8 billion (+56% YoY) and non-GAAP EPS of $8.55, beating estimates. The company raised its full-year 2026 revenue guidance to $82-$85 billion, driven by strong sales of Mounjaro and Zepbound. This significant growth and guidance raise is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Reported Q1 2026 financial results, posting a GAAP Loss per Share of $1.72, which included a $3.62 per share charge from the acquisition of Cidara Therapeutics. Revenue grew 5% to $16.3 billion. The company raised its full-year 2026 guidance; high importance due to guidance raise and acquisition impact, market reaction expected.
4/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
High importance estimated as this regulatory change protects core revenue from competition, likely impacting price by >10%. The U.S. FDA proposed to exclude the active ingredients in key Novo Nordisk GLP-1 drugs from the bulk compounding list.
4/30/2026, 12:00:00 AM